Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)

Efficace, F; Buckstein, R; Abel, GA; Giesinger, JM; Fenaux, P; Bewersdorf, JP; Brunner, AM; Bejar, R; Borate, U; DeZern, AE; Greenberg, P; Roboz, GJ; Savona, MR; Sparano, F; Boultwood, J; Komrokji, R; Sallman, DA; Xie, Z; Sanz, G; Carraway, HE; Taylor, J; Nimer, SD; Della Porta, MG; Santini, V

Journal article : Review

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)

Abstract:: Notable treatment advances have been made in recent years for patients with myelodysplastic syndromes/neoplasms (MDS), and several new drugs are under development. For example, the emerging availability of oral MDS therapies holds the promise of improving patients' health‐related quality of life (HRQoL). Within this rapidly evolving landscape, the inclusion of HRQoL and other patient‐reported outcomes (PROs) is critical to inform the benefit/risk assessment of new therapies or to assess wheth...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Efficace, F., Buckstein, R., Abel, G. A., Giesinger, J. M., Fenaux, P., Bewersdorf, J. P., Brunner, A. M., Bejar, R., Borate, U., DeZern, A. E., Greenberg, P., Roboz, G. J., Savona, M. R., Sparano, F., Boultwood, J., Komrokji, R., Sallman, D. A., Xie, Z., Sanz, G., … Santini, V. (2024). Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS). HemaSphere, 8(5).

MLA Style

Efficace, F., et al. “Toward a More Patient‐Centered Drug Development Process in Clinical Trials for Patients with Myelodysplastic Syndromes/Neoplasms (MDS): Practical Considerations from the International Consortium for MDS (IcMDS).” HemaSphere, vol. 8, no. 5, Wiley Open Access, 2024.

Chicago Style

Efficace, F, R Buckstein, GA Abel, JM Giesinger, P Fenaux, JP Bewersdorf, AM Brunner, et al. 2024. “Toward a More Patient‐Centered Drug Development Process in Clinical Trials for Patients with Myelodysplastic Syndromes/Neoplasms (MDS): Practical Considerations from the International Consortium for MDS (IcMDS).” HemaSphere 8 (5).
Tweet
Print